Literature DB >> 11021505

Voice-related quality of life (V-RQOL) following type I thyroplasty for unilateral vocal fold paralysis.

N D Hogikyan1, W P Wodchis, J E Terrell, C R Bradford, R M Esclamado.   

Abstract

Unilateral vocal fold paralysis is a common clinical problem which frequently causes severe dysphonia. Various treatment options exist for this condition, with the type I thyroplasty being one of the more commonly performed surgical procedures for vocal rehabilitation. The Voice-Related Quality of Life (V-RQOL) Measure is a validated outcomes instrument for voice disorders. This study measured the V-RQOL of patients with unilateral vocal fold paralysis who had undergone a type I thyroplasty and compared these scores to those of patients with untreated and uncompensated unilateral vocal fold paralysis and to normals. Treated patients had significantly higher domain and overall V-RQOL scores than untreated patients, but also scored lower than normals. These differences were true across gender and age. Patients who were more distant from surgery had lower V-RQOL scores than those who had more recently been treated. It is concluded that type I thyroplasty leads to a significantly higher V-RQOL for patients with unilateral vocal fold paralysis. This study also demonstrates further the utility of patient-oriented measures of treatment outcome.

Entities:  

Mesh:

Year:  2000        PMID: 11021505     DOI: 10.1016/s0892-1997(00)80083-1

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  13 in total

1.  Throat related symptoms and voice: development of an instrument for self assessment of throat-problems.

Authors:  Roland Rydell; Jacqueline Eriksson; Lucyna Schalén; Viveka Lyberg-Åhlander
Journal:  BMC Ear Nose Throat Disord       Date:  2010-05-27

2.  Vocal fold surgery of benign inflammatory lesions of Reinke's space: an outcome study in 47 subjects.

Authors:  Joost J S van Dinther; Marc De Bodt; Floris L Wuyts; Paul H Van de Heyning
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-05-16       Impact factor: 2.503

3.  [Treatment of glottal gap].

Authors:  S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2013-02       Impact factor: 1.284

Review 4.  Voice outcome indicators for unilateral vocal fold paralysis surgery: a review of the literature.

Authors:  G Desuter; M Dedry; B Schaar; J van Lith-Bijl; P P van Benthem; E V Sjögren
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-20       Impact factor: 2.503

5.  Multidimensional assessment of functional outcomes of medialization thyroplasty.

Authors:  Virgilijus Uloza; Ruta Pribuisiene; Viktoras Saferis
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-12-10       Impact factor: 2.503

6.  Medialization versus reinnervation for unilateral vocal fold paralysis: a multicenter randomized clinical trial.

Authors:  Randal C Paniello; Julia D Edgar; Dorina Kallogjeri; Jay F Piccirillo
Journal:  Laryngoscope       Date:  2011-09-06       Impact factor: 3.325

7.  Dysphonia: medical treatment and a medical voice hygiene advice approach. A prospective randomised pilot study.

Authors:  M Pedersen; A Beranova; S Møller
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-14       Impact factor: 2.503

8.  Predictors of Six-month Change in the Voice Handicap Index in a Treatment-seeking Population.

Authors:  Jaime Moore; Caprice Greenberg; Susan L Thibeault
Journal:  J Voice       Date:  2016-03-04       Impact factor: 2.009

9.  The role of immediate recurrent laryngeal nerve reconstruction for thyroid cancer surgery.

Authors:  Tetsuji Sanuki; Eiji Yumoto; Ryosei Minoda; Narihiro Kodama
Journal:  J Oncol       Date:  2010-06-14       Impact factor: 4.375

10.  Neuromonitoring in thyroidectomy: a meta-analysis of effectiveness from randomized controlled trials.

Authors:  Alvaro Sanabria; Adonis Ramirez; Luiz P Kowalski; Carl E Silver; Ashok R Shaha; Randall P Owen; Carlos Suárez; Avi Khafif; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.